According to the National Cancer Institute, more than 333,000 new cases of prostate cancer will be diagnosed in the United States, making it the second-leading cause of cancer death among American men as approximately 1 in 8 men receive a diagnosis during their lifetime, per American Cancer Society data. While those figures appear daunting, medical … Read more
Researchers have identified a urinary tract bacterium capable of converting the steroid precursor DHEA into testosterone under laboratory conditions, revealing a previously unknown microbial pathway that could impact prostate biology, according to a study supervised by Jason M. Ridlon. The finding does not indicate that the bacterium causes prostate cancer or that the microbial testosterone … Read more
Stereotactic body radiation therapy improves bowel health-related quality of life for patients with localized intermediate-risk prostate cancer compared to moderately hypofractionated intensity-modulated radiation therapy, according to findings from the NRG-GU005 clinical trial published in the Journal of the American Medical Association. NRG-GU005 Trial Design and Patient Demographics The Phase III NRG-GU005 trial evaluated 698 evaluable … Read more
Researchers at the Keck School of Medicine of USC have identified a 3D hierarchy of DNA “enhancers” that function as master switches for prostate cancer development. According to a study published in Genome Biology, these interconnected networks control gene expression, revealing potential new targets for precision cancer therapies that could move beyond current gene-specific treatments. … Read more
Cardiovascular risk calculators currently used by doctors to predict heart attacks and strokes can also estimate a patient’s risk of developing certain cancers, according to a study published in the European Journal of Cancer. Researchers at University College London (UCL) found that tools like QRISK3—widely used in the UK—performed with comparable accuracy to specialized cancer … Read more
The Stockholm3 blood test identifies clinically significant prostate cancer more effectively than traditional Prostate-Specific Antigen (PSA) screening, according to a study published in the Annals of Internal Medicine. Researchers at Karolinska Institutet found the new test detected 90 percent of aggressive tumors compared to 74 percent for PSA, without increasing the rate of unnecessary follow-up … Read more
Researchers at the MUSC Hollings Cancer Center have identified a mechanism that allows prostate cancer cells to survive treatment by hijacking a protein called PIM1. According to a study published in Cancer Letters, traditional therapies that block PIM1 signaling inadvertently trigger a survival response, prompting the team to develop a “degrader” compound known as PIMTAC … Read more
Americans with the highest levels of obesity are undergoing fewer surgical procedures, despite a rising national prevalence of severe obesity. A study published in the journal Obesity, which analyzed 11.6 million surgical cases between 2005 and 2022, found that patients with higher body mass index (BMI) levels are increasingly underrepresented in surgical care for common … Read more
The Invisible Threat: Why Standard Scans Are Failing Prostate Cancer Patients Imagine receiving a report from your doctor stating that your bone scan is perfectly clear. You breathe a sigh of relief, thinking the cancer is contained. But beneath the surface, a silent progression is already underway. This is the harrowing reality for a significant … Read more
Revolutionizing Prostate Cancer Care: The Future of Personalized Radiotherapy For patients battling metastatic castration-resistant prostate cancer (mCRPC), the path to effective treatment is often complex. A breakthrough in machine learning is now offering a glimpse into a more precise future, where clinicians can estimate radiation doses to tumors and healthy organs before therapy even begins. … Read more